A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Sara Bobisse; Valentina Bianchi; Janos L Tanyi; Apostolos Sarivalasis; Edoardo Missiaglia; Rémy Pétremand; Fabrizio Benedetti; Drew A Torigian; Raphael Genolet; David Barras; Alexandra Michel; Spyridon A Mastroyannis; Emese Zsiros; Denarda Dangaj Laniti; Zoi Tsourti; Brian J Stevenson; Christian Iseli; Bruce L Levine; Daniel E Speiser; David Gfeller; Michal Bassani-Sternberg; Daniel J Powell Jr; Carl H June; Urania Dafni; Lana E Kandalaft; Alexandre Harari; George Coukos

doi:10.1038/s43018-023-00623-x

A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

Nat Cancer. 2023 Oct;4(10):1410-1417. doi: 10.1038/s43018-023-00623-x. Epub 2023 Sep 21.

Authors

Sara Bobisse^#^{1

2}, Valentina Bianchi^#^{1

2

3}, Janos L Tanyi^#⁴, Apostolos Sarivalasis², Edoardo Missiaglia^{5

6}, Rémy Pétremand^{1

2}, Fabrizio Benedetti^{1

2}, Drew A Torigian⁷, Raphael Genolet^{1

2}, David Barras^{1

2}, Alexandra Michel^{1

2}, Spyridon A Mastroyannis⁴, Emese Zsiros^{4

8}, Denarda Dangaj Laniti^{1

2}, Zoi Tsourti⁹, Brian J Stevenson^{1

2

6}, Christian Iseli^{6

10}, Bruce L Levine¹¹, Daniel E Speiser², David Gfeller^{1

2

6}, Michal Bassani-Sternberg^{1

2}, Daniel J Powell Jr¹¹, Carl H June¹¹, Urania Dafni⁹, Lana E Kandalaft^#^{1

2

3}, Alexandre Harari^#^{1

2}, George Coukos^#^{12

13}

Affiliations

¹ Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland.
² Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
³ Center for Experimental Therapeutics, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
⁴ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
⁵ Institute of Pathology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland.
⁶ SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
⁷ Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
⁸ Department of Gynecologic Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
⁹ Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
¹⁰ Bioinformatics Competence Center, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
¹¹ Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA.
¹² Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne, Lausanne, Switzerland. george.coukos@chuv.ch.
¹³ Center for Cell Immunotherapy, Department of Oncology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland. george.coukos@chuv.ch.

^# Contributed equally.

PMID: 37735588
DOI: 10.1038/s43018-023-00623-x

Abstract

We have previously shown that vaccination with tumor-pulsed dendritic cells amplifies neoantigen recognition in ovarian cancer. Here, in a phase 1 clinical study ( NCT01312376 /UPCC26810) including 19 patients, we show that such responses are further reinvigorated by subsequent adoptive transfer of vaccine-primed, ex vivo-expanded autologous peripheral blood T cells. The treatment is safe, and epitope spreading with novel neopeptide reactivities was observed after cell infusion in patients who experienced clinical benefit, suggesting reinvigoration of tumor-sculpting immunity.

Publication types

Clinical Trial, Phase I

MeSH terms

Adoptive Transfer
Female
Humans
Ovarian Neoplasms* / therapy
T-Lymphocytes
Vaccination
Vaccines*

Substances

Vaccines

Abstract

Publication types

MeSH terms

Substances

Grants and funding